W R Berkley Reports In-Line Q4 Earnings with Sales Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: Benzinga
- Earnings Meet Expectations: W R Berkley reported Q4 earnings of $1.13 per share, aligning perfectly with analyst consensus, indicating stable profitability for the company.
- Sales Exceed Estimates: The company achieved quarterly sales of $3.721 billion, surpassing the analyst estimate of $3.661 billion, demonstrating strong market demand.
- Slight Stock Decline: Despite the solid performance, W R Berkley shares fell 0.4% to close at $63.83 on Monday, reflecting market caution regarding future growth.
- Analyst Target Adjustments: Analysts from BofA Securities and Mizuho lowered their price targets for W R Berkley from $69 to $66 and $67 respectively, indicating a conservative outlook on the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WRB
Wall Street analysts forecast WRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WRB is 72.25 USD with a low forecast of 64.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 68.260
Low
64.00
Averages
72.25
High
84.00
Current: 68.260
Low
64.00
Averages
72.25
High
84.00
About WRB
W. R. Berkley Corporation is an insurance holding company. It operates through two segments of the property casualty insurance business: Insurance and Reinsurance & Monoline Excess. Its Insurance businesses underwrite commercial insurance business, including excess and surplus lines, admitted lines and specialty personal lines throughout the United States, as well as insurance business in Asia, Australia, Canada, Continental Europe, Mexico, Scandinavia, South America and the United Kingdom. Its Insurance segment consists of business units, including Acadia Insurance, Admiral Insurance, Berkley Accident and Health, Berkley Agribusiness and others. It provides professional liability and casualty insurance for small to mid-sized businesses though the business unit Berkley Edge. Its Reinsurance & Monoline Excess offers reinsurance business on a facultative and treaty basis in the United States, United Kingdom, Continental Europe, Australia, the Asia-Pacific region and South Africa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
W R Berkley Reports In-Line Q4 Earnings with Sales Beat
- Earnings Meet Expectations: W R Berkley reported Q4 earnings of $1.13 per share, aligning perfectly with analyst consensus, indicating stable profitability for the company.
- Sales Exceed Estimates: The company achieved quarterly sales of $3.721 billion, surpassing the analyst estimate of $3.661 billion, demonstrating strong market demand.
- Slight Stock Decline: Despite the solid performance, W R Berkley shares fell 0.4% to close at $63.83 on Monday, reflecting market caution regarding future growth.
- Analyst Target Adjustments: Analysts from BofA Securities and Mizuho lowered their price targets for W R Berkley from $69 to $66 and $67 respectively, indicating a conservative outlook on the company's future performance.
Continue Reading
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
Continue Reading